Analysts maintain a bullish outlook on AbbVie, with comprehensive analysis available through InvestingPro's detailed research reports, which provide deeper insights into the company's growth prospects ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan ... REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through ...

She is the co-founder of PowerZone Trading, a company that has provided programming, consulting, and strategy development services to active traders and investors since 2004. Diane Costagliola is ...

If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.

We can see that AbbVie does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and ...